Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF3 | O95398 | 16/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 0.68 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20523712 | 0.93 | RAPGEF3 (1.00) | RAPGEF3ALBRAPGEF4 | |
| SCHEMBL20523644 | 0.90 | RAPGEF3 (1.00) | RAPGEF3ALBRAPGEF4MEN1KMT2A | |
| SCHEMBL20523754 | 0.90 | RAPGEF3 (1.00) | RAPGEF3ALBRAPGEF4 | |
| SCHEMBL20523674 | 0.86 | RAPGEF3 (1.00) | RAPGEF3ALBRAPGEF4MEN1LMNA | |
| SCHEMBL15173845 | 0.84 | RAPGEF3 (0.76) | RAPGEF3ALBRAPGEF4MEN1LMNA | |
| SCHEMBL15173844 | 0.84 | RAPGEF3 (0.76) | RAPGEF3ALBRAPGEF4MEN1LMNA | |
| SCHEMBL20523698 | 0.83 | RAPGEF3 (0.77) | RAPGEF3 | |
| SCHEMBL20523645 | 0.83 | RAPGEF3 (1.00) | RAPGEF3 | |
| SCHEMBL20523700 | 0.82 | RAPGEF3 (1.00) | RAPGEF3 | |
| SCHEMBL15941194 | 0.81 | RAPGEF3 (1.00) | RAPGEF3ALBRAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124489-B2 | EPAC antagonists | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-09-21 | — | — | US | disclosed |
| US-20200255388-A1 | EPAC ANTAGONISTS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-08-13 | — | — | US | disclosed |
| WO-2018183626-A1 | EPAC ANTAGONISTS | ZHOU JIA (US) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255388-A1 | EPAC ANTAGONISTS | EPAS1, GPR139, CRACR2A | RAPGEF3 5/4885ALB 4570/4885RAPGEF4 7/4885 |
| US-11124489-B2 | EPAC antagonists | EPAS1, GPR139, CRACR2A | RAPGEF3 5/4885ALB 4570/4885RAPGEF4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.